AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

SynAct Pharma Board/Management Information 2024

Feb 27, 2024

3114_rns_2024-02-27_b5bcd091-67b0-48a5-aa99-73dc980c8780.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Marina Bozilenko resigns from Board of Directors of SynAct Pharma

SynAct Pharma AB (publ) ("SynAct") announced today Marina Bozilenko has notified the Board of her resignation as member of the Board of Directors due to personal reasons.

"We are grateful for Marina's time and effort serving on the Board. She has been a valuable asset to SynAct. We wish her the best of luck," said SynAct Chairman Uli Hacksell.

"I very much enjoyed working with the management team and Board of Directors of SynAct, but unfortunately my personal and professional commitments have increased a great deal and I am no longer able to contribute adequate time and effort to SynAct. I resign my position with regret and wish the company and everyone involved a productive and successful future," said Marina Bozilenko.

For further information, please contact:

Uli Hacksell

Chairman, SynAct Pharma AB Email: [email protected]

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www. synactpharma.com.

Attachments